恩度联合GP方案治疗晚期NSCLC的近期疗效

陈群; 谢强; 石琴; 肖松

doi:10.3971/j.issn.1000-8578.2011.02.021

恩度联合GP方案治疗晚期NSCLC的近期疗效

Short-term Efficacy of YH-16 Combined with GP Regimen for Advanced Non-small Cell Lung Cancer

摘要

摘要: 目的观察恩度(重组人血管内皮抑素, YH-16)联合GP方案(吉西他滨+顺铂)治疗晚期非小细胞肺癌的近期临床疗效，评价恩度临床应用的安全性和耐受性。方法GP + YH-16 (治疗组)和GP (对照组)方案化疗两周期。结果治疗组客观有效率为45.5%,疾病控制率为90.9%，症状缓解率为81.8%，生活质量改善率为63.6%；对照组分别为34.3%, 71.4%，60.0%，40.0% ；除客观有效率比较差异无统计学意义外(P>0.05)，其余指标比较差异均有统计学意义(P<0.05)。不良反应多数是1/2级，主要与化疗有关，治疗组出现4例心悸和心率失常。结论恩度与GP方案联合应用，能提高晚期NSCLC 的疾病控制率，能在一定程度上缓解弥漫性肺小结节转移灶和浆膜腔积液，从而改善肺功能和生活质量，且安全性较好。

Abstract: ObjectiveTo investigate the short-term efficacy and toxicity of YH-16 combined with GP regimen for NSCLC. MethodsThe patients were divided into GP + YH-16 （trial group) and GP （control group), and the efficacy and toxicity were evaluated after 2 cycles according to RECIST criteria. ResultsThe trial group's effective rate was 45.5% while the control group was 34.3%, P>0.05. For three other results:the disease control rate symptomatic relief rate and QOL improvement rate,they were 90.9%, 81.8% and 63.6% in the trial group and 71.4%, 60.0% and 40.0% in the control group respectively, P<0.05. Side effects were almostly grade 1/2 and concened with chemotherapy. 4 patients in the trial group suffered cardiopalmus and arrhythmias. ConclusionThe combination of YH-16 with GP regimen could improve the disease control rate of advanced NSCLC obviously, relieving metastasis focus of tumor, reducing the serous pleural effusion, improving lung function. Besides, side effects was less than those of others.

HTML全文

参考文献(0)

施引文献

资源附件(0)